key: cord-1036120-zhbyn8s0
authors: Bergamaschi, Cristina; Terpos, Evangelos; Rosati, Margherita; Angel, Matthew; Bear, Jenifer; Stellas, Dimitris; Karaliota, Sevasti; Apostolakou, Filia; Bagratuni, Tina; Patseas, Dimitris; Gumeni, Sentiljana; Trougakos, Ioannis P.; Dimopoulos, Meletios A.; Felber, Barbara K.; Pavlakis, George N.
title: Systemic IL-15, IFN-γ and IP-10/CXCL10 Signature Associated with Effective Immune Response to SARS-CoV-2 in BNT162b2 mRNA Vaccine Recipients
date: 2021-07-23
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109504
sha: 775705999561952f38b16dcc3ff0e351ca45d28f
doc_id: 1036120
cord_uid: zhbyn8s0

Early responses to vaccination are important in shaping both humoral and cellular protective immunity. Dissecting innate vaccine signatures may predict immunogenicity to help optimizing efficacy of mRNA and other vaccine strategies. We characterized the cytokine and chemokine responses to the 1st and 2nd dose of the BNT162b2 mRNA (Pfizer/BioNtech) vaccine in antigen-naïve and in previously COVID-19-infected individuals (NCT04743388). Transient increases in IL-15 and IFN-γ levels early after boost correlated with Spike antibody levels, supporting their use as biomarkers of effective humoral immunity development in response to vaccination. We identified a systemic signature including IL-15, IFN-γ and IP-10/CXCL10 increase after the 1st vaccination, which was enriched by TNF-α and IL-6 after the 2nd vaccination. In previously COVID-19-infected individuals, a single vaccination resulted in both strong cytokine induction and antibody titers similar to the ones observed upon booster vaccination in antigen-naïve individuals, a result with potential implication for future public health recommendations.

SARS-CoV-2 has infected more the 131 million individuals worldwide and is responsible for more than 2.8 million deaths to date (https://www.coronavirustraining.org/live-map). Infection or vaccination is associated with development of variable levels of antibodies with neutralizing activity that can protect against infection and/or disease development in animal models (reviewed in (Munoz-Fontela et al., 2020) ). Administration of neutralizing anti-Spike antibodies (NAb) was shown to provide strong protection from disease in animal models and humans (Baum et al., 2020; Chen et al., 2021; Gottlieb et al., 2021; Ledford, 2021; Weinreich et al., 2021) . Several SARS-CoV-2 vaccines currently tested induced potent antibody responses in humans, which led to the advancement of several candidates to the clinic under Emergency Use Authorization or Conditional Marketing Authorization and demonstrated protective efficacy (Baden et al., 2021; Barrett et al., 2021; Folegatti et al., 2020; Polack et al., 2020; Sadoff et al., 2021; Stephenson et al., 2021; van Doremalen et al., 2020; Walsh et al., 2020; Widge et al., 2021) . SARS-CoV-2 vaccines showed real-world effectiveness as reported in Israel (Chodick et al., 2021) as well as by CDC USA (Report, 2021a) and Public Health England (Report, 2021b).

Cytokines and chemokines are important drivers of inflammation and innate immunity and have a pivotal role in the development and maintenance of adaptive immunity, in response to both infection and vaccination. Identification of a robust signature of cytokine induction leading to successful vaccination would be important for further vaccine development and optimization (Arunachalam et al., 2020; Fourati et al., 2019; Hagan and Pulendran, 2018; Kuri-Cervantes et al., 2016) . Immune signatures in vaccine recipients receiving Yellow fever, HIV-Ade5 or HIV ALVAC vaccines have been described (Andersen-Nissen et al., 2021; Gaucher et al., 2008; Querec et al., 2009; Zak et al., 2012) .

J o u r n a l P r e -p r o o f 6 8). The antibody responses did not further increase upon the 2 nd vaccination and remained significantly higher than in the SARS-CoV-2 naïve vaccine recipients (orange asterisks).

Analysis of the kinetics of Spike-RBD and Spike antibody development in the 58 naïve vaccine recipients showed a maximal level reached after the 2 nd vaccination. The Spike-RBD ( Figure 1A) , but not the anti-Spike (Figure 1B) , antibody levels contracted significantly by day 50 in these recipients. The difference could be explained by the different antibody half-lives and is corroborated by our report that antibodies to Spike-RBD have a shorter half-life than antibodies to complete Spike (Terpos, 2021) . The observed differences reflect the nature of these antibodies not only in convalescent patients (Terpos, 2021) but also in mRNA vaccinated persons, therefore, this is a general feature of the antibody specificities.

The neutralizing ability of these antibodies was measured using a surrogate virus neutralization test (GenScript; Figure 1C ), an assay that reached a median of 96% inhibition after the 2 nd dose, making any further comparisons uncertain, and a Spike pseudotyped Nanoluc reporter virus assay, performed in a subset of samples selected to cover a range of low to highest responses ( Figure 1D ). Overall NAb levels followed those of the binding antibodies. The pseudotype NAb levels correlated significantly with the anti-Spike-RBD ( Figure S2A ) and anti-Spike antibodies ( Figure S2B ), as expected from our studies of convalescent patients and of vaccinated macaques (Rosati et al., 2021; Terpos et al., 2020; Terpos et al., 2021a) , supporting that antibody measurements (Spike and Spike-RBD) can serve as surrogate for NAb measurements.

For the 5 recipients with pre-existing COVID-19 immunity one single vaccination induced potent recall responses with maximal antibody levels reached by day 8 for both Spike-RBD antibodies and NAb (Figure 1) , similar to recent findings reported while this report was in J o u r n a l P r e -p r o o f preparation (Ebinger et al., 2021; Gobbi et al., 2021; Manisty et al., 2021) . These levels did not decline within the 4-week follow-up post 2 nd vaccination (day 22 or day 50) in contrast to the decline found in 86% of the naïve vaccine recipients (49 of 57 paired samples). Thus, a single vaccination in the presence of pre-existing immunity due to CoV-2 infection induced faster and more durable immune responses. Based on these results, subsequent analysis of serum cytokines and chemokines was performed in SARS-CoV-2 naive (N=58) versus previously infected (N=5) vaccine recipients.

Sera collected on the day of and after the 1 st and the 2 nd vaccination (d1, d2, d8 and d22, d23, respectively) were subjected to cytokine/chemokine analysis using the MSD platform (Meso Scale Discovery) analyzing 41 analytes (Supplemental Table S2 ). Of these, 19 analytes showed significant changes, 8 showed none or marginal changes and 14 were below the threshold of detection.

The chemokine/cytokine levels showing changes (Figure 2, Figure S3 ) include molecules released in response to inflammation with both a pro-inflammatory role (IL-6, VEGF-A and acute phase proteins SAA and CRP) (Hunter and Jones, 2015; Mangalmurti and Hunter, 2020) and anti-inflammatory function (IL-1Ra) (Dinarello, 2018; Mantovani et al., 2019) ; chemokines involved in lymphocyte, monocyte/macrophage and granulocyte recruitment (IP-10/CXCL10, IL-8, IL-16, MIP-1/CCL3, MIP-1/CCL4MCP-1/CCL2, MDC/CCL22 and Eotaxin) (Griffith et al., 2014) ; cytokines that promote innate and adaptive immune response (IFN-, IL-15, IL-12/IL-23p40, TNF-, IL-3 and IL-7) (Hu and Ivashkiv, 2009; Leonard et al., 2019) .

J o u r n a l P r e -p r o o f 8 The cytokine/chemokine profile induced by the 1 st and 2 nd vaccination and the comparison between the effects induced by each dose for the individual recipients are represented in heatmaps ( Figure 3A and Figure 3D ).

After the 1 st vaccination the 58 naive vaccine recipients showed a highly significant but transient increase of IFN-~2.5x; Figure 2AIP -10/CXCL10 (~2x; Figure 2B) , and IL-6 (1.5x; Figure 2C ) at day 2 followed by rapid downregulation close to baseline levels by day 8.

IL-15 also showed a small but significant upregulation (Figure 2A) . Other analytes including IL-8 (~3x; Figure 2B ), IL-16(~1.5x; Figure 2B ), MIP-1/CCL3~2.5x; Figure 2B , MIP-1/CCL4 (~1.5x; Figure 2B ), IL-1Ra (~2x; Figure 2C ) were significantly upregulated over baseline both at day 2 and day 8, indicating longer lasting vaccine effects (one week after administration). No significant differences after the 1 st vaccination were observed for TNF- (Figure 2A) , MCP-1/CCL2 ( Figure 2B ) and IL-3 ( Figure S3) . A slight decrease in IL-12/IL-23p40, MDC/CCL22 and IL-7 levels ( Figure S3 ) was also observed, while CRP, Eotaxin, SAA and VEGF-A were all increased ( Figure S3 ) as consequence of the inflammation process. For the majority of the analytes, serum levels at day 22, prior to 2 nd vaccination, were comparable to pre-vaccination as shown in the heatmap ( Figure 3A ).

The cytokine/chemokine response pattern was different at day 23 (one day after the 2 nd vaccination, Figure 2 , Figure S3 , Figures 3D to 3F) . showed elevated levels at day 23 that were significantly higher than day 2 (Figure 2) . not affected, while MIP-1/CCL3 and IL-1Ra behave similarly after each vaccine dose ( Figures   2B and 2C ). Eotaxin showed a slight downregulation at day 23 ( Figure S3) . Importantly, TNF- (Figure 2A) , MCP-1/CCL2 (Figure 2B) , IL-7 (Figure S3 ), IL-3 ( Figure S3 ) and IL-12/IL-23p40 ( Figure S3 ) showed significant increases only after the 2 nd vaccination (day 23; Figure 2 , Figure S3 ).

To confirm our results, we also performed differential expression analysis comparing mean cytokine levels for the 58 naïve vaccine recipients at day 2 to day 1 (Figure 3B Figure S3 ). IL-15 upregulation also reached significance using FDR<0.05 ( Figure   3E ). For several analytes (IFN-, IP-10/CXCL10, IL-15, IL-6, CRP, MIP-1), the log2 fold change were higher after the 2 nd vaccination ( Figure 3E) . The differential outcome of the 2 nd vaccination versus 1 st vaccination is represented in a volcano plot ( Figure 3F ).

Vaccine recipient clustering did not reveal a differential effect of the vaccination on the cytokine/chemokine profile based on age (cut-off age 50) in this cohort. However, we found stronger induction in female versus male vaccine recipients ( Figure S4 ) of IFN-IL-15, IL-6 and IP-10/CXCL10 upon the 2 nd vaccination. Since the dominant adverse effect (AE) upon the vaccinations ( Table S3 ) was pain at site of injection as reported by 80% and 76% of vaccinees, respectively, this precluded further dissection of AE and cytokine/chemokine changes.

A similar chemokine/cytokine analysis was performed in the 5 vaccine recipients with preexisting SARS-CoV-2 immunity. The cytokine/chemokine signature upon the 1 st and 2 nd vaccination is depicted in heatmaps ( Figure 4A and 4B) . The effects of the 1 st vaccination were also compared among the 2 vaccine groups (Figures 4C to 4F ). In recipients with pre-existing CoV-2 immunity, the 1 st vaccination induced a much stronger upregulation of IFN-, IP-Overall, these data showed that BNT162b2 mRNA vaccination is accompanied by the rapid release in the blood of inflammatory markers, chemokines and cytokines. In particular, the vaccination resulted in a strong response driven by IL-15, IFN- and IP-10/CXCL10. Booster vaccination in naïve individuals or one single vaccine dose in previously SARS-CoV-2 infected individuals induced anamnestic responses and higher levels of cytokines critical for the rapid recruitment and stimulation of virus-specific effector immune cells.

mRNA vaccination results in an innate signature characterized by the co-expression of several cytokines and chemokines. In order to assess the inter-relationship of the vaccine-induced effects on different serum cytokines and chemokines, we performed pairwise correlation analysis using the log2 fold change at day 2 (1 st vaccination) and day 23 (2 nd vaccination).

Effects at day 2 (upon 1 st vaccination) identified positive associations in a cluster featuring IL-15, IFN-, IP-10/CXCL10 and IL-6 ( Figure S5 ). However, these associations (Spearman r between 0.25 and 0.42, Figure S5 ) were below our cut-off for a Spearman correlation coefficient corresponding to an adjusted p value <0.05. The cytokine signature at day 2 suggested rapid coexpression of molecules promoting inflammation and priming of adaptive immunity. Indeed, a role of IL-15 in inducing both IFN- directly and IP-10/CXCL10 through the IFN type 2 pathway has been previously reported (Bergamaschi et al., 2020) . Additionally, in autoimmune conditions such as rheumatoid arthritis, localized inflammatory responses are characterized by the concerted release of both IL-15 and IL-6 that are maintained by positive feedback loops and results in systemic disorders (McInnes and Schett, 2011) .

A correlation matrix of the measurements after the 2 nd vaccination was also calculated ( Figure 5A ). Several cytokines were co-expressed upon the 2 nd vaccination and individual correlation plots of cytokines within the red and grey boxes in the heatmap are shown in Figure   5B and Figure S6 , respectively. A concerted and highly significant effect on IL-15, IFN-, TNF-, IL-6 and IP-10/CXCL10 was observed ( Figure 5A , red box), suggesting an amplification of the responses already induced at day 2 upon the 1 st vaccination ( Figure S5 ). Among the cytokine pairs correlated highly, we identified IL-15 and IFN-, IL-15 and TNF-, IL-15 and IL-6, IL-15 and IP-10/CXCL10, IFN- and TNF-, IFN- and IL-6, IFN- and IP-10/CXCL10, TNF-and IL-6TNF-and IP-10/CXCL10and IL-6 and IP-10/CXCL10 ( Figure 5B ). These results are consistent with a coordinate role of these cytokines in supporting both innate and adaptive immunity and in the recall of immune memory response.

Additionally, correlations suggesting a generic pattern of cytokine/chemokine co-expression as consequence of the inflammation process were also identified. The day 23 IL-15 log2 fold change significantly correlated with the day 23 log2 fold change for MIP-1/CCL4 and IL-1Ra (Table S4) .

Interestingly, significant correlations include several cytokines belonging to clusters of coexpression as reported in Figure 5 . These results suggest a coordinated response to the vaccine and highlight the important role of innate responses to vaccination in shaping adaptive immunity.

We found the same correlation of biomarkers with anti-Spike antibody responses, when we performed a similar analysis using the antibody titers elicited against full-length trimeric Spike J o u r n a l P r e -p r o o f upon the 2 nd vaccination (d36), confirming a positive association with the log2 fold changes at day 23 for both IFN- (r=0.58, p<0.0001) and IL-15 (r=0.51, p<0.0001) (Figures 6C and 6D , respectively). These data are expected based on the strong correlations on Spike-RBD and Spike antibody levels ( Figure S1 ).

Together, these results suggest a coordinated response to the vaccine and highlight the important role of innate responses to vaccination in shaping adaptive immunity.

The field of vaccination against infectious diseases has witnessed rapid advances during the COVID-19 pandemic, with the clinical introduction of novel platforms and especially mRNAbased vaccines. Such novel vaccine technologies as the BNT162b2 mRNA COVID-19 vaccine elicit a range of responses but the mechanisms that determine the quality and quantity of these responses are largely uncharacterized (Teijaro and Farber, 2021) . In the present study, we applied systems serology to study the effects of the BNT162b2 mRNA COVID-19 vaccine to identify immunological parameters predictive of beneficial response to mRNA-based vaccination. Our analysis on the circulating levels of cytokines, chemokines and inflammation markers as well as on the generation of anti-Spike-RBD antibodies suggests that cytokine modulation could indeed be a biomarker of successful vaccination resulting in efficient antibody development.

In antigen-naïve individuals, the 1 st vaccination resulted in both acute and more persistent effects on serum cytokine/chemokine levels (up to one week after dose administration), that were a result of inflammation and innate immune system activation. Broader and greater cytokine changes were observed after 2 nd vaccination, suggesting also stimulation of anamnestic responses. Indeed, BNT162b2 mRNA vaccine administration induced a systemic J o u r n a l P r e -p r o o f cytokine/chemokine signature featuring IL-15, IFN-and IP-10/CXCL10, molecules with a pivotal role in eliciting innate immune responses as well as in shaping adaptive immunity and leading to immunological memory. Importantly, changes in the level of IFN- and IL-15 positively correlated with antibody titers against SARS-CoV-2 Spike-RBD. Several associations between cytokine alterations were also identified, suggesting a coordinate response to the vaccine.

Immune signatures in vaccine recipients receiving Yellow fever, HIV-Ade5 or HIV ALVAC vaccines have been described (Andersen-Nissen et al., 2021; Gaucher et al., 2008; Querec et al., 2009; Zak et al., 2012) . These studies underscored the importance of analysis within 24 hrs after vaccination to determine innate signatures and early biomarkers that shape and predict protective adaptive responses elicited by different vaccine platforms. Analyzing the effect of a non- Biomarkers could also help the refinement of regimens to increase vaccine efficacy and applicability and distribution, through the identification of individuals with supra-or sub-optimal responses, especially during an outbreak. In our study, the early cytokine profile and the antibody titers induced by one single mRNA vaccination in persons with pre-existing COVID-19 immunity mimics the response to the booster vaccination in COVID-naïve persons. These findings support the proposal of administering a single vaccine dose to individuals with preexisting SARS-CoV-2 immunity, useful during the present period of limited vaccine supply. This conclusion is in agreement with recent publications (Ebinger et al., 2021; Gobbi et al., 2021; Manisty et al., 2021) .

IL-15 is a heterodimeric cytokine, comprising the IL-15 and IL-15 receptor alpha chains, termed hetIL-15 (Bergamaschi et al., 2012; Bergamaschi et al., 2008; Bergamaschi et al., 2021; Chertova et al., 2013) . It affects both the innate and adaptive immune system, by supporting proliferation, survival and function of many lymphocytes (Berard et al., 2003; Carson et al., 1994; Ma et al., 2006; Picker et al., 2006; Zhang et al., 1998) . IL-15 possesses a non-redundant role in supporting long-lasting immune responses (Li et al., 2015; Rubinstein et al., 2008; Schluns et al., 2002) and in stimulating cytotoxic activity of immune cells (Bergamaschi et al., 2020; Ng et al., 2017; Watson et al., 2018) . In a humanized mouse model, IL-15 treatment resulted in the development of T cell-dependent antigen-specific B responses, following immunization (Huntington et al., 2011) . These functions provided the rationale for exploring the use of IL-15 in conjunction with vaccination and evaluating its role in promoting immunogenicity. Indeed, several studies demonstrated enhanced immune response to different J o u r n a l P r e -p r o o f vaccine platforms by IL-15 (Moore et al., 2002; Oh et al., 2003) . We have also previously showed that the use of hetIL-15 as molecular adjuvant in the therapeutic vaccination of SIVinfected macaques resulted in robust induction of SIV-specific effector memory cells and virological benefit with strong reduction of viremia (Valentin et al., 2010) . .

Both IFN-and IP-10/CXCL10 play a role in the IL-15 effects on the immune system. IL-15 directly stimulates lymphocytes to produce IFN-. Both type I and type II IFN responses, in conjunction with IL-15, often represent the first innate barrier against pathogens (Perera et al., 2012) . In addition, IFN- is critical for the development and maintenance of type 1 and antiviral immune responses (reviewed in (Lin and Young, 2014; Schroder et al., 2004) ). An involvement of IFN- in shaping humoral responses by controlling immunoglobulin isotypes produced by B cells and supporting long-lived antibody-secreting cells has also been documented (Baumgarth, 2021; Stone et al., 2019) .

The chemokine IP-10/CXCL10 is often released in the context of inflammation by many cells including leukocytes, neutrophils, eosinophils, monocytes and stromal cells, in response to IFN-γ. IP-10/CXCL10 promotes the chemotaxis of CXCR3 + cells, mainly activated T and B lymphocytes (reviewed in (Griffith et al., 2014; Liu et al., 2011) ). A recent study proposed a mechanism by which IL-15 indirectly acts on dendritic cells and macrophage/monocytes to induce the secretion of IP-10/CXCL10, via IFN- (Bergamaschi et al., 2020) . Recent studies identified early innate immune responses to both flu and Ebola vaccines. Serum IP-10/CXCL10 levels, innate signature linked to IP-10/CXCL10 and IFN-related genes were associated with higher vaccine-induced antibody titers (Goncalves et al., 2019; Rechtien et al., 2017) . IP-Given their action, IL-15, IFN- and IP-10/CXCL10 have emerged as critical components of an immune response against viral infections. In our study, the role of these cytokines upon vaccination became more apparent after the 2 nd vaccination, that also induced TNF- and IL-6. Importantly, a similar cytokine/chemokine pattern of expression at 24 hours post-vaccination was found between vaccine recipients with pre-existing SARS-CoV-2 immunity who received the 1 st vaccine dose and antigen-naïve individuals after 2 nd vaccine dose, suggesting induction of anamnestic responses, with higher levels of IFN-, IP-10/CXCL10, IL-6 and TNF- for the rapid recruitment and stimulation of effector immune cells.

Many studies have shown that uncontrolled inflammation and cytokine storm syndrome contribute to the severity of COVID-19 disease. Patients with severe disease are characterized by high levels of inflammatory markers, including CRP, ferritin, D-dimer, high levels of chemokines such as granulocyte colony-stimulating factor (G-CSF), MCP-1/CCL2, MIP-1/CCL3, IL-8 and IP-10/CXCL10 resulting in inflammatory cell infiltration and tissue damage in the lungs and in high neutrophil-to-lymphocyte ratio (Mehta et al., 2020; Merad and Martin, 2020) . A systemic increase in the levels of IL-2, IL-7, IL-10, IL-6 and TNF- has also been reported . In particular, IL-6, IL-8 and TNF- serum levels are significant predictors of disease severity and death (Del Valle et al., 2020) . In contrast, early activation of IFN type I pathway was associated with prevention of disease progression Zhang et al., 2020) . Although several of the cytokines and chemokines induced by viral infection were also elevated after mRNA vaccination, important differences are to be highlighted. Upon vaccination, we observed an early but transient inflammatory cytokine response. IFN-, IP-chemokines IL-8, IL-16, MIP-1/CCL3, MIP-1/CCL4. In contrast, in COVID-19 patients, systemic levels of IP-10/CXCL10 and IL-6 remain elevated throughout the COVID-19 infection response (Buszko et al., 2021) . Additionally, the vaccine-induced up-regulation of the antiinflammatory molecule IL-1Ra may also indicate a self-modulatory and limiting inflammatory effect of the vaccine. Importantly, our data suggest that mRNA vaccination is associated with a cytokine signature featuring IL-15, IFN- and IP-10/CXCL10, that results in an efficient antiviral immune response, usually weakened in COVID-19 patients.

In conclusion, this study highlights important associations of several immunoregulatory molecules induced by vaccination with innate and adaptive immune responses elicited by an mRNA-based vaccine. The early cytokine/chemokine signature featuring IL-15, IFN- and IP-10/CXCL10 may be used to monitor effective vaccination and as a guide to optimize efficacy of mRNA vaccination strategies.

Conceptualization: George N. Pavlakis, Barbara K. Felber; Evangelos Terpos, Meletios A. 

The authors declare no competing interests.

We worked to ensure gender balance in the recruitment of human subjects. We worked to ensure ethnic or other types of diversity in the recruitment of human subjects. We worked to ensure that the study questionnaires were prepared in an inclusive way. While citing references scientifically relevant for this work, we also actively worked to promote gender balance in our reference list.

Vaccine recipients were monitored after vaccination 1 (d1, d8, d22) and at weeks 2 and 4 post 2 nd vaccination (d36, d50). Responses are shown for recipients with pre-existing immunity due to prior infection (orange symbols) and vaccine recipients naïve to SARS-CoV-2 (black symbols).

Over time analysis of binding antibodies recognizing (A) anti-Spike-RBD IgG (ROCHE, U/ml in log) and (B) full-length trimeric Spike (ELISA, endpoint titer in log) are shown. The Spike-RBD IgG antibody assay (ROCHE) has a range of >0.4 -2,500 U/ml and was run with serial dilutions for some samples reaching >50,000 U/ml. Neutralizing antibodies were assessed by (C) a surrogate virus neutralization test (GenScript) and (D) pseudotype NAb assays using HIV-1 NL ΔEnv-NanoLuc derived pseudotype virus carrying Wuhan-Hu-1 Spike. Pseudotype neutralization was performed in sera from 5 vaccinees with pre-existing immunity and a subset of samples selected to cover a range of low to high responses (N=25 naïve vaccinees; black symbols) at d22 and d36. Sera from vaccinees with pre-existing immunity showed pseudotype Nab titers (ID50) with a median 3.6 log (range 3.2-3.9) upon a single vaccination with similar levels after the booster vaccination (median 3.8 log; range 3.5-4.1). Naïve vaccinees showed NAb ID50 titers ranging from 0.1-2.94 log at d22 and from 1.79-3.78 log at d36. The surrogate virus inhibition assay showed median 96% inhibition levels after the 2 nd dose (>90% inhibition by 95% of d36 sera and by 83% of d50 sera, respectively). (A, C) Median Spike-RBD antibody and % inhibition and response rate (%) are listed. Orange asterisks indicate significant difference between vaccine recipient with or without prior immunity to SARS-CoV-2 (Mann-Whitney test).

See also Figures S1, S2 and Table S1 . Figure S4 , Tables S2 and S3.

Cytokine and chemokine levels were measured using the MSD assay after the 1 st and 2 nd vaccination in 5 recipients with pre-existing immunity (as described for fold changes for TNF- (E) and IL-6 (F). P values are from unpaired non-parametric t test (Mann-Whitney). See also Tables S2 and S3.

Pairwise correlations were calculated among the log2 fold changes at day 23 (after the 2 nd vaccination) for the 19 biomarkers that were affected by the vaccination, using the Spearman correlation coefficient (adjusted p-value < 0.05). The analysis was performed for the 58 COVID-19 naïve vaccine recipients. (A) Correlation matrix for the 2 nd vaccination is plotted as heatmap. 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Barbara K. Felber (Barbara.felber@nih.gov).

This study did not generate new unique reagents.

 Data and analysis generated during the study are available at https://github.com/NCI-VB/felber_covid_vaccine.

 This paper does not report original code.

 Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

This is an ongoing prospective study (NCT04743388) that evaluates the kinetics of antibodies against SARS-CoV-2 as well as the kinetics of serum cytokines and chemokines associated with the immune response and of B-and T-cell subpopulations in volunteers receiving the BNT162b2 vaccine against SARS-Cov-2 (Comirnaty TM ) initiated on January 4, 2021, in Greece. This analysis reports the results regarding the alterations of cytokines and chemokines in volunteer donors, which is a secondary endpoint of the study.

Major inclusion criteria for participation in this study included: (i) age above 18 years; (II) ability to sign the informed consent form, and (iii) eligibility for vaccination, according to the national (Greek) program for COVID-19 vaccination (i.e. individuals who had no serious allergy problem and especially they have not been hospitalized due to a serious allergic reaction (anaphylaxis). Major exclusion criteria included the presence of: (i) autoimmune disorder under immunosuppressive therapy; (ii) active malignant disease and (iii) end-stage renal disease, as previously described (Terpos et al., 2021b) .

Volunteer donors between the ages of 20-78 (Male=27 and Female=36) were tested in the period January 4 to April 1, 2021, in the vaccine center of Alexandra General Hospital in Athens,

Greece. All study procedures were carried out in accordance with the declaration of Helsinki 

Serum was collected at day of vaccination (d1) and 1 and 3 weeks later (d8, d22) and 2 and 4 weeks after the 2 nd vaccination dose (d36 and d50). After vein puncture, serum was separated within 4 hours from blood collection and stored at -80°C until the day of measurement. Stored samples from different time points of the same donor were measured in parallel assays.

Anti-Spike-RBD IgG antibodies and neutralizing antibodies (NAbs) against SARS-CoV-2

were measured using FDA approved methods, i.e., the Elecsys Anti-SARS-CoV-2 S assay J o u r n a l P r e -p r o o f (Roche Diagnostics GmbH, Mannheim, Germany) (Higgins et al., 2021) and the cPass™ SARS-CoV-2 NAbs Detection Kit (GenScript, Piscataway, NJ, USA) (Tan et al., 2020) , respectively; the latter allows the indirect detection of potential SARS-CoV-2 NAbs in the blood, by assaying the antibody (independent of class)-mediated inhibition of SARS-CoV-2 RBD binding to human host receptor angiotensin converting enzyme 2 (ACE2).

An in-house ELISA assay described elsewhere (Terpos et al., 2020; Terpos et al., 2021a) was used to detect the complete trimeric Spike using mammalian Expi293-cells produced proteins (Esposito et al., 2020) measuring eight 4-fold serial dilutions starting at 1:50. Antibody levels were expressed as endpoint titers using a model fit approach conducted in R to model the curve to more accurately define endpoint titers (Terpos et al., 2021a) .

The Spike pseudotyped pHIV NL Env-Nanoluc assay (Robbiani et al., 2020; Schmidt et al., 2020) was performed as previously described (Terpos et al., 2020; Terpos et al., 2021a) . Spike Table S2 ). For analysis, biomarkers falling below the J o u r n a l P r e -p r o o f 29 detection limit/standard range were removed if absent in more than 50% of the samples or adjusted to 0.5 of the lowest standard point/detection limits.

Biomarker analysis was performed with a workflow written in R and through a user interface developed on the Foundry Platform (Palantir Technologies). The limma package was used to compare biomarker changes between timepoints, setting significance for False Discovery Rate 

All software is freely or commercially available and is listed in the STAR Methods description and Key Resources Table. J o u r n a l P r e -p r o o f Supplemental Information Table S1 . Relevant history of vaccine recipients with pre-existing CoV-2 immunity, Related to J o u r n a l P r e -p r o o f Table S4 . Correlations of anti-Spike antibodies at day 36 and cytokines log2 fold changes upon 2 nd vaccination (d23-d22), Related to Figure 6 .

Anti-Spike antibody endpoint titer d22 (log)

Spike-RBD IgG d22 (U/ml, log)

Spike-RBD IgG d36 (U/ml, log) Anti-Spike antibody endpoint titer d36 (log) NAb assays were performed in using a HIV-1 NL ΔEnv-NanoLuc derived pseudotype neutralization assay in HEK-ACE2 cells using Wuhan-Hu-1 Spike. using sera from a subset of naïve vaccinees (day 36) selected to cover a range of low to high responses. Correlations of (A) Spike-RBD (ROCHE, log) and (B) antibodies against full length trimeric Spike (ELISA, endpoint titer in log) and pseudotype NAb measured at day 36 (samples from Figure 1 ). Spearman r and p values are given (GraphPad Prism). Correlations of log2 fold changes of selected analytes after the 2 nd vaccination are shown derived from data depicted in heatmap in Figure 5A (grey box). r is shown in plots; all correlations are characterized by an adjusted p<0.05.

Innate immune signatures to a partially-efficacious HIV vaccine predict correlates of HIV-1 infection risk

Systems biological assessment of immunity to mild versus severe COVID-19 infection in humans

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Autoantibodies against type I IFNs in patients with life-threatening COVID-19

REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters

The Shaping of a B Cell Pool Maximally Responsive to Infections

IL-15 promotes the survival of naive and memory phenotype CD8+ T cells

Circulating IL-15 exists as heterodimeric complex with soluble IL-15Ralpha in human and mouse serum

Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-gamma, CXCL9 and CXCL10

Its Receptor {alpha} during Production Leads to Mutual Stabilization and Increased Bioactivity

Heterodimeric IL-15 in Cancer Immunotherapy

Lessons learned: new insights on the role of cytokines in COVID-19

Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans. Vaccines (Basel) 9

Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19

Characterization and favorable in vivo properties of heterodimeric soluble IL-15.IL-15Ralpha cytokine compared to IL-15 monomer

The effectiveness of the TWO-DOSE BNT162b2 vaccine: analysis of real-world data

An inflammatory cytokine signature predicts COVID-19 severity and survival

Overview of the IL-1 family in innate inflammation and acquired immunity

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, singleblind, randomised controlled trial

Integrated systems approach defines the antiviral pathways conferring protection by the RV144 HIV vaccine

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection

Innate gene signature distinguishes humoral versus cytotoxic responses to influenza vaccination

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial

Chemokines and chemokine receptors: positioning cells for host defense and immunity

Will Systems Biology Deliver Its Promise and Contribute to the Development of New or Improved Vaccines? From Data to Understanding through Systems Biology

Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation

Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

IL-6 as a keystone cytokine in health and disease

IL-15 transpresentation promotes both human T-cell reconstitution and T-cell-dependent antibody responses in vivo

Systems biology and the quest for correlates of protection to guide the development of an HIV vaccine

COVID antibody treatments show promise for preventing severe disease

The gammac Family of Cytokines: Basic Biology to Therapeutic Ramifications

Differential effects of IL-15 on the generation, maintenance and cytotoxic potential of adaptive cellular responses induced by DNA vaccination

Interferons: Success in anti-viral immunotherapy

CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications

Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis

Cytokine Storms: Understanding COVID-19

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity

The pathogenesis of rheumatoid arthritis

COVID-19: consider cytokine storm syndromes and immunosuppression

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice

Animal models for COVID-19

Heterodimeric IL-15 treatment enhances tumor infiltration, persistence and effector functions of adoptively transferred tumor-specific T cells in the absence of lymphodepletion

Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity

The role of interleukin-15 in inflammation and immune responses to infection: implications for its therapeutic use

IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV

CDC COVID-19 Study Shows mRNA Vaccines Reduce Risk of Infection by 91

PHE monitoring of the effectiveness of COVID-19 vaccination

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques

IL-7 and IL-15 differentially regulate CD8+ T-cell subsets during contraction of the immune response

Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine

Cutting edge: requirement for IL-15 in the generation of primary and memory antigen-specific CD8 T cells

Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses

Interferon-gamma: an overview of signals, mechanisms and functions

Immunogenicity of the Ad26.COV2.S Vaccine

T-bet Transcription Factor Promotes Antibody-Secreting Cell Differentiation by Limiting the Inflammatory Effects of IFNgamma on B Cells

A SARS-CoV-2 surrogate virus neutralization test based on antibodymediated blockage of ACE2-spike protein-protein interaction

COVID-19 vaccines: modes of immune activation and future challenges

Anti-SARS-CoV-2 Antibody Responses in Convalescent Plasma Donors Are Increased in Hospitalized Patients

SARS-CoV-2 antibody kinetics eight months from COVID-19 onset: Persistence of spike antibodies but loss of neutralizing antibodies in 24% of convalescent plasma donors

Age-and genderdependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine

Repeated DNA therapeutic vaccination of chronically SIV-infected macaques provides additional virological benefit

nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Treatment with native heterodimeric IL-15 increases cytotoxic lymphocytes and reduces SHIV RNA in lymph nodes

REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19

Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Macrophages induce differentiation of plasma cells through CXCL10/IP-10

Merck Ad5/HIV induces broad innate immune activation that predicts CD8(+) T-cell responses but is attenuated by preexisting Ad5 immunity

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

Potent and selective

We thank R. Burns for assistance, Y. Wang and J. Inglefield, Clinical Services Program, Frederick National Laboratory for Cancer Research for technical assistance; D. Donohue (Data Management Service, NCI) for assistance with data analysis; T. Hatziioanou (Rockefeller